A complex increase in hepatitis C virus in a correctional facility: bumps in the road.
Aboriginal and Torres Strait Islander
hepatitis C
injecting drugs
prison
Journal
Australian and New Zealand journal of public health
ISSN: 1753-6405
Titre abrégé: Aust N Z J Public Health
Pays: United States
ID NLM: 9611095
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
revised:
01
10
2021
received:
01
05
2021
accepted:
01
02
2022
pubmed:
19
4
2022
medline:
10
6
2022
entrez:
18
4
2022
Statut:
ppublish
Résumé
The prevalence of hepatitis C virus (HCV) in correctional facilities in Australia among people who inject drugs is 60%, with disproportionate effects observed in Aboriginal and Torres Strait Islander people. Following the micro-elimination of HCV in a Queensland correctional facility (QCF), newly acquired cases began to increase in mid-2019. Here we discuss the public health response to increasing HCV in a QCF. Enhanced surveillance was performed to obtain contextual outbreak data on risk factors including injecting drug use, sharing of personal hygiene equipment and do-it-yourself-tattooing. In the sixteen months, there were 250 notifications of new and re-infected HCV infections in prisoners in the QCF. Qualitative data revealed the leading factor in transmission to be injecting drug use. Drivers for increased HCV transmission in correctional facilities include boredom, waiting lists for opioid substitution programs, changes in injecting behaviours and sharing of injecting paraphernalia. Point-of-care testing combined with education and the development of a needle and syringe program may be promising ways forward for managing HCV in correctional facilities. Correctional facilities are key locations to target sexually transmitted infection (STI) and blood-borne virus (BBV) testing and treatment as well as health promotion to improve the health of inmates and the communities they return to.
Identifiants
pubmed: 35435996
doi: 10.1111/1753-6405.13238
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
377-381Informations de copyright
© 2022 The Authors.
Références
Bartlett SR, Fox P, Cabatingan H, Jaros A, Gorton C, Lewis R, et al. Demonstration of near-elimination of hepatitis C virus among a prison population: The Lotus Glen Correctional Centre Hepatitis C Project. Clin Infect Dis. 2018;67:460-3.
The Lowitja Institute. Evaluation of Lotus Glen Correctional Centre Aboriginal and Torres Strait Islander Peer Education Project. Melbourne (AUST): The Institute; 2020.
The Kirby Institute. Surveillance and Treatment of Prisoners with Hepatitis C (SToP-C). Sydney (AUST): University of New South Wales; 2020,
Dolan D, Sacha-Krol D, Vumbaca G. A Needs Analysis for People Living with HCV after Leaving Custodial Settings in Australia. Canberra (AUST): Australian Injecting and Illicit Drug Users League; 2017.
Rance J, Lafferty L, Treloar C. ‘Behind closed doors, no one sees, no one knows’: Hepatitis C, stigma and treatment-as-prevention in prison. Crit Public Health. 2018;30(2):130-40.
Kamarulzaman A, Reid SE, Schwitters A, Wiessing L, El-Bassel N, Dolan K, et al. Prevention of transmission of HIV, hepatitis B virus, hepatitis C virus, and tuberculosis in prisoners. Lancet. 2016;388(10049):1115-26.
Heymann DL. Control of Communicable Diseases Manual. 20th ed. Washington (DC): American Public Health Association; 2015.
PWC Indigenous Consulting. Indigenous Incarcerations: Unlock the Facts. Melbourne (AUST): PWC; 2017.
Ausralian Bureau of Statistics. Prisoners in Australia. Canberra (AUST): ABS; 2020.
Smirnov A, Kemp R, Ward J, Henderson S, Williams S, Dev A, et al. Hepatitis C viral infection and imprisonment among Aboriginal and Torres Strait Islander and nonIndigenous people who inject drugs. Drug Alcohol Rev. 2018;37(7):831-6.
Kirby Institute. HIV, Viral Hepatitis and Sexually Transmissible Infections in Australia: Annual Surveillance Report. Sydney (AUST): University of New South Wales; 2018.
McCormack H. Hepatitis C and Aboriginal and Torres Strait Islander people: Closing the gap. HIV Aust. 2016;14(1):27.
Gastroenterological Society of Australia. Australian Recommendations for the Management of Hepatitis C Virus Infection: A Consensus Statement (September 2018). Melbourne (AUST): GESA; 2018.
Khoo A, Tse E. A practical overview of the treatment of chronic hepatitis C virus infection. Aust J Gen Pract. 2016;45(10):718.
Pharmaceutical Benefits Scheme. Sofosbuvir and Velpatasvir. Canberra (AUST): Australian Government Department of Health; 2021.
Grebely J, Prins M, Hellard M, Cox AL, Osburn WO, Lauer G, et al. Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: Towards a vaccine. Lancet Infect Dis. 2012;12(5):408-14.
Kaneko R, Nakazaki N, Omori R, Yano Y, Ogawa M, Sato Y. Efficacy of direct-acting antiviral treatment for chronic hepatitis C: A single hospital experience. World J Hepatol. 2018;10(1):88-94.
Australian Health Practitioner Regulation Agency. The National Scheme's Aboriginal and Torres Strait Islander Health and Cultural Safety Strategy 20202025. Melbourne (AUST): AHPRA; 2020.
Australian Institute of Health and Welfare. National Drug Strategy Household Survey Detailed Report 2013. Canberra (AUST): AIHW; 2014.
MacRae A, Hoareau J. Review of Illicit Drug Use Among Aboriginal and Torres Strait Islander People. Mount Lawley (AUST): Edith Cowan University Australian Indigenous HealthInfoNet; 2016.
Australian Institute of Health and Welfare. Alcohol, Tobacco and Other Drugs in Australia. Canberra (AUST): AIHW; 2021.
Bryant J, Ward J, Wand H, Byron K, Bamblett A, WaplesCrowe P, et al. Illicit and injecting drug use among Indigenous young people in urban, regional and remote Australia. Drug Alcohol Rev. 2016;35(4):447-55.
Woodall J. Social and environmental factors influencing inprison drug use. Health Educ. 2011;112(1):31-46.
Sazzad HMS, McCredie L, Treloar C, Lloyd AR, Lafferty L. Violence and hepatitis C transmission in prison-A modified social ecological model. PLoS One. 2020;15(12):e0243106.
Queensland Corrective Services. Queensland Corrective Services Annual Report 2019-20. Brisbane (AUST): State Government of Queensland; 2020.
Corrective Services Regulation 2017 (QLD).
Butler T, Richmond R, Belcher J, Wilhelm K, Wodak AJTC. Should smoking be banned in prisons? Tob Control. 2007;16(5):291-3.
de Andrade D, Kinner SA. Systematic review of health and behavioural outcomes of smoking cessation interventions in prisons. Tob Control. 2017;26(5):495-501.
Hefler M, Hopkins R, Thomas D. Successes and unintended consequences of the Northern Territory's smoke-free prisons policy: Results from a process evaluation. Public Health Res Pract. 2016;26:e2621619.
Boelen L, Teutsch S, Wilson DP, Dolan K, Dore GJ, Lloyd AR, et al. Per-event probability of hepatitis C infection during sharing of injecting equipment. PLoS One. 2014;9(7):e100749.
Australian Institute of Health and Welfare. Drug Use Among Aborignal and Torres Strait Islander Peoples. Canberra (AUST): AIHW; 2006.
Skye Kinder. Ethical justice: Needle and syringe programs in Australian prisons. Insight. 2020;April 27.
Abdul-Quader AS, Feelemyer J, Modi S, Stein ES, Briceno A, Semaan S, et al. Effectiveness of structural-level needle/syringe programs to reduce HCV and HIV infection among people who inject drugs: A systematic review. AIDS Behav. 2013;17(9):2878-92.
Australian Government Department of Health. Return on Investment 2: Evaluation the Cost-effectiveness of Needle and Syringe Programs in Australia 2009: Introduction and Brief Review of Prior Studies. Canberra (AUST): Government of Australia; 2009.
Niveau G. Relevance and limits of the principle of “equivalence of care” in prison medicine. J Med Ethics. 2007;33(10):610-13.
Rutter S, Dolan KA, Wodak A, Heilpern H. Prison-Based Syringe Exchange Programs: A Review of International Research and Program Development. Sydney(AUST): University of New South Wales National Drug & Alcohol Research Centre; 2001.
Australian Government Department of Health. Needle and Syringe Programs: A Review of the Evidence. Canberra (AUST): Government of Australia; 2005.
Kronfli N, Buxton JA, Jennings L, Kouyoumdjian F, Wong A. Hepatitis C virus (HCV) care in Canadian correctional facilities: Where are we and where do we need to be? Can Liver J. 2019;2(4):171-83.
United Nations Office on Drugs and Crime. A Handbook for Starting and Managing Needle and Syringe Programs in Prisons and Other Closed Settings. Beirut (LBN): UNODC; 2014.
Harkness B, Levy M, Evans R, Wenke J. Why is there still hepatitis C transmission in Australian prisons? A case report. Harm Reduct J. 2017;14(1):75.